BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24201120)

  • 1. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.
    Gianelli U; Bossi A; Cortinovis I; Sabattini E; Tripodo C; Boveri E; Moro A; Valli R; Ponzoni M; M Florena A; F Orcioni G; Ascani S; Bonoldi E; Iurlo A; Gugliotta L; Franco V
    Mod Pathol; 2014 Jun; 27(6):814-22. PubMed ID: 24201120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
    Campr V
    Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
    Tovar-Bobadilla JL; Ortiz-Hidalgo C
    Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
    Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
    Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
    Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
    Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
    Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K; Bock O; Kreipe H
    Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool.
    Rudzki Z; Kawa R; Okoñ K; Szczygieł E; Stachura J
    Virchows Arch; 2006 Jan; 448(1):59-67. PubMed ID: 16220296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM; Thiele J
    Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of the registry for Philadelphia-negative chronic myeloproliferative neoplasia in Hungary].
    Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Udvardy M; Egyed M
    Orv Hetil; 2016 Jan; 157(3):98-103. PubMed ID: 26750731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
    Shallis RM; Zeidan AM; Wang R; Podoltsev NA
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):177-189. PubMed ID: 33641862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada.
    Heppner J; Nguyen LT; Guo M; Naugler C; Rashid-Kolvear F
    BMC Res Notes; 2019 May; 12(1):286. PubMed ID: 31126326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
    Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
    Rev Med Chil; 2021 Dec; 149(12):1687-1693. PubMed ID: 35735335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
    Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
    Rev Med Chil; 2021 Nov; 149(11):1532-1538. PubMed ID: 35735314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.